

þ

Apotex







Apotex Corp., headquartered in Weston, Florida, is the U.S. affiliate of Apotex Inc., the 7th largest generic pharmaceutical company in the world. Apotex employs over 10,000 people and can produce up to 24 billion dosages a year across a full range of dosage forms, including tablets, capsules, oral suspensions, ophthalmic, nasals and liquid products. These products are sold into more than 120 countries around the world. A strong pipeline of over 300 more products in development is the key to keeping this strong market presence.

Frequently recognized for superior service by customers, Apotex Corp. is ranked in the top ten U.S. generic pharmaceutical manufacturers by sales and is 10th in total generic prescriptions, according to recent IMS HEALTH data. Apotex's expansive product portfolio spans a wide range of therapeutic classes, including cardiovascular, antiinfectives, gastrointestinal, central nervous system, mental health, pain management and respiratory. The company continues to diversify its product mix by adding new therapeutic areas and dosage forms such as transdermal patches and injectables. Recently, Apotex launched the first generic version of Merck's Nasonex® nasal spray (mometasone furoate monohydrate) in the United States.

"We are very pleased to make a more affordable version of this important allergy medicine available to the U.S. public. Apotex is dedicated to bringing high quality versions of complex generic products to market, and we are delighted that these efforts will generate substantial savings for the U.S. healthcare system." said Apotex Chief Executive Officer and President, Dr. Jeremy B. Desai.

Apotex has long been known for building strong industry partnerships to champion the cause of making affordable medicines and driving down healthcare costs. One such partnership is with the Generic Pharmaceutical Association (GPhA). In February of this year, Jeff Watson, President, Global Generics was appointed to the 2016 GPhA Board of Directors. "This industry continues to be the most reliable source of savings in the health sector," said Watson. "I look forward to working with the association leadership to advance the mission of GPhA and its member companies, improving the lives of millions of patients while enhancing timely access to quality, affordable medicines."

A Forward-Thinking Approach

Apotex is passionate in its approach to research and development. The company will spend \$2 billion in the next ten years on R&D, with a significant portion of those resources focused on the company's emerging biosimilar program. Apotex currently has two biosimilar applications (filgrastim [Neupogen®] and pegfilgrastim [Neulasta®]) under active review with the FDA. "We are very pleased to be at the forefront of companies who will introduce high quality biosimilar products into the U.S. marketplace," said Dr. Desai. "Our entry into this new frontier of medicine is a watershed event in Apotex's 42-year history of providing quality, affordable medicines to patients in need around the globe."

Reliable Advocate and Trusted Partner

000001

http://www.pharmacytimes.com/publications/supplement/2016/generic-supplement-2016/apotex-advancing-generics

We want to know your top recommended OTC products!

Pharmacy Times® and U.S. News would like to hear what OTC products you most often recommend. You will have the chance to win an **iPhone X!**



Pharmacist Education Clinical features with downloadable PDFs

> Exhibit 1131 IPR2017-00807 ARGENTUM ^{1/3}

2/22/2018

Apotex

Apotex believes all manufacturers have a corporate citizenship responsibility to the global community. The company carries out this responsibility through various national initiatives and partnerships and continues to donate life-saving medicines to developing countries to alleviate human suffering and save the lives of many people around the world. Apotex is committed to serving patients by advancing generics and providing high quality, affordable products.

For more information, visit www.apotexcorp.com.



Pharmac biometric for to by y pharmace y

Top 200 Drugs of 2010

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER



Apotex

2/22/2010					Apolex				
	<u>Careers</u>	<u>Contact Us</u>	<u>Feedback</u>	<u>Advertise With Us</u>	Terms & Conditions	<u>Privacy</u>	Press Room	Conference Coverage	
Copyright © 2006-2017 Pharmacy & Healthcare Communications, LLC. All Rights Reserved.									